Antidepressants -- Brain Damage and Chronic Brain Impairments
SSRI or SNRI Antidepressants:
Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment. Verdoux H, Cougnard A, Thiebaut A, Tournier M. Pharmacopsychiatry, 2011 May; 44(3) 96-101
The authors studied data on 35,053 persons starting antidepressant treatment. They found "The risk of re-initiation of antidepressant treatment was higher if the duration of the index episode of
antidepressant treatment was [greater than] ≥ 6 months [hazard ratio (HR)=2.35; 95% CI 2.25-2.45) or 2-5 months (HR=1.65; 95% CI 1.59-1.71) compared to ≤ 1 month." In other words, the longer a patient is exposed to antidepressants, the greater is the risk that there will be another episode of depression requiring another round of antidepressant prescriptions.
"Tardive dysphoria: The role of long term antidepressant use in inducing chronic depression," Rif S. El-Mallakh, Yonglin Gao, R. Jeannie Roberts, Medical Hypotheses 76 (2011) 769-773
"...emerging evidence that, in some individuals, persistent use of antidepressants may be prodepressant."
"Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression" Paul W. Andrews, etal, Frontiers in Psychology, July 7, 2011
The authors document that antidepressant drugs increase the risk of relapse of depression for patients. They further comment on the growing habit of treating depression with multiple psychiatric drugs stating "Since many patients on antidepressants alone do not achieve full remission (Rush et al., 2006), possibly due to oppositional tolerance, atypical antipsychotic drugs, and other agents are increasingly prescribed to enhance the efﬁcacy of ADMs. Our results suggest that the concurrent use of multiple drugs could cause greater monoaminergic perturbations, possibly further increasing the risk of relapse after they are discontinued."
Efficacy and Effectiveness of Antidepressants: Current Status of Research, H. Edmund Pogott, Allan M. Leventhal, Gregory S. Alter, John J. Boren. Psychotherapy and Psychosomatics, 2010; 79:267-269
“Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study” Wongpakaran N., etal, Annals of General Psychiatry, 2007 6:7
“Selective Serotonin Reuptake Inhibitor-Induced Apathy: A Pediatric Case Series,” Reinblatt S.P. etal, J of Child and Adolescent Psychopharmacology, 16:1/2, 2006 227-233
“Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain,” Zhou, L. etal, Journal of Neurochemistry, 2006, 96. 396-406
"SSRI-Induced Apathy Syndrome: A Clinical Review," Barnhart W.J., etal, J of Psychiatric Practice 10:3 May 2004
“Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial” Deakin J.B., etal, Psychopharmacology (2004) 172:400-408
“Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?” Opbroek, A. etal, Intl. J of Neuropsychopharmacology 2002, 5, 147-151
“Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus,” Malberg J. etal, J of Neuroscience, 20:24 December 15, 2000, pp 9104-9110
“Persistently Increased Density of Serotonin Transporters in the Frontal Cortex of Rats Treated with Fluoxetine During Early Juvenile Life,” Wegerer V. etal, J of Child and Adolescent Psychopharmacology 9:1, 1999
“Apathy and Indifference in Patients on Fluvoxamine and Fluoxetine,” Hoehn-Saric R. etal, J Clin Psychopharmacol Vol 10:5, Oct 1990
"Modification of Serotonergic Neuron Properties by Long-Term Treatment With Serotonin Reuptake Blockers", Claude de Montigny, et al, J Clinical Psychiatry Dec. 1990 [This 1990 published study is "not allowed to be posted" by the Journal of Clinical Psychiatry to be made available for Fair Use and has been removed from website October 2, 2015 after email received from Maureen Bunner-Hunsucker, Physicians Postgraduate Press, requesting removal for "copyright infringement." This paper provides some of the earliest evidence that Prozac and other SSRIs cause permanent damage to neurotransmission in the brain. One of the authors, Montigny, once told Dr. Breggin that he wouldn't do even longer term studies because it might hurt Eli Lilly. See Breggin, P. and Breggin, G. bestselling book Talking Back to Prozac. Dr. Breggin suspects that Eli Lilly is behind this otherwise ridiculous suppression of scientific research and communication that was published at this writing, 25 years ago. This is a perfect example of why scientists and other throughout the world are calling for the free access to all scientific publications and studies. Shame on the Journal of Clinical Psychiatry.]
“Receptor Alterations Associated With Serotonergic Agents: An Autoradiographic Analysis,” Wamsley J. etal, J Clin Psychiatry 48:3 (Suppl) March 1987
"Midlife vs Late-Life Depressive Symptoms and Risk of Dementia" Deborah E. Barnes, PhD, MPH et al, Arch Gen Psychiatry May 2012
Fair Use Notice:
These links may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is used for non-profit educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. Any copyright owner who objects to the use of their copyrighted material should send an e-mail to EmpathicTherapy@hotmail.com